Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study.
Chandrakasan S, Allen CE, Bhatla D, Carter J, Chien M, Cooper R, Draper L, Eckstein OS, Hanna R, Hays JA, Hermiston ML, Hinson AP, Hobday PM, Isakoff MS, Jordan MB, Leiding JW, Modica R, Nakano TA, Oladapo A, Patel SA, Pednekar P, Riskalla M, Sarangi SN, Satwani P, Tandra A, Walkovich KJ, Yee JD, Zoref-Lorenz A, Behrens EM; REAL‐HLH investigators. Chandrakasan S, et al. Among authors: zoref lorenz a. Arthritis Rheumatol. 2024 Sep 8. doi: 10.1002/art.42985. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 39245963
Controlling HLH: dealing JAKs from the pack.
Zoref-Lorenz A. Zoref-Lorenz A. Blood. 2024 Jun 6;143(23):2342-2344. doi: 10.1182/blood.2024024412. Blood. 2024. PMID: 38842858 No abstract available.
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
Chandrakasan S, Jordan MB, Baker A, Behrens EM, Bhatla D, Chien M, Eckstein OS, Henry MM, Hermiston ML, Hinson AP, Leiding JW, Oladapo A, Patel SA, Pednekar P, Ray AK, Dávila Saldaña B, Sarangi SN, Walkovich KJ, Yee JD, Zoref-Lorenz A, Allen CE. Chandrakasan S, et al. Among authors: zoref lorenz a. Blood Adv. 2024 May 14;8(9):2248-2258. doi: 10.1182/bloodadvances.2023012217. Blood Adv. 2024. PMID: 38429096 Free PMC article.
Inpatient recognition and management of HLH.
Zoref-Lorenz A, Ellis M, Jordan MB. Zoref-Lorenz A, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):259-266. doi: 10.1182/hematology.2023000509. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066887 Free PMC article. Review.
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
Geerlinks AV, Scull B, Krupski C, Fleischmann R, Pulsipher MA, Eapen M, Connelly JA, Bollard CM, Pai SY, Duncan CN, Kean LS, Baker KS, Burroughs LM, Andolina JR, Shenoy S, Roehrs P, Hanna R, Talano JA, Schultz KR, Stenger EO, Lin H, Zoref-Lorenz A, McClain KL, Jordan MB, Man TK, Allen CE, Marsh RA. Geerlinks AV, et al. Among authors: zoref lorenz a. Blood Adv. 2023 Jul 25;7(14):3725-3734. doi: 10.1182/bloodadvances.2022009478. Blood Adv. 2023. PMID: 37042921 Free PMC article.
17 results